KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

NovoCure (NVCR) Other Operating Expenses (2016 - 2026)

NovoCure's Other Operating Expenses history spans 13 years, with the latest figure at $58.4 million for Q1 2026.

  • On a quarterly basis, Other Operating Expenses rose 4.6% to $58.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $242.6 million, a 1.24% increase, with the full-year FY2025 number at $240.1 million, changed 0.42% from a year prior.
  • Other Operating Expenses hit $58.4 million in Q1 2026 for NovoCure, down from $68.7 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for NVCR hit a ceiling of $68.7 million in Q4 2025 and a floor of $37.9 million in Q1 2022.
  • Historically, Other Operating Expenses has averaged $55.2 million across 5 years, with a median of $57.1 million in 2025.
  • Biggest five-year swings in Other Operating Expenses: surged 40.03% in 2023 and later fell 3.2% in 2024.
  • Tracing NVCR's Other Operating Expenses over 5 years: stood at $49.6 million in 2022, then grew by 19.26% to $59.2 million in 2023, then rose by 13.89% to $67.4 million in 2024, then grew by 1.85% to $68.7 million in 2025, then fell by 15.01% to $58.4 million in 2026.
  • Business Quant data shows Other Operating Expenses for NVCR at $58.4 million in Q1 2026, $68.7 million in Q4 2025, and $58.5 million in Q3 2025.